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detrimental  effects,  the  mHAg-induced 
alloimmune response also causes the cura-
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poietic system–restricted (7). mHAgs are 















































as  well  (11).  Protocols  have  been  estab-
lished for the in vitro generation of donor-
derived HA-1– or HA-2–specific CTLs to 






















































of  this  approach  is  that  the  identified 
Table 1
Immunotherapeutic mHAgs
mHAg	 mHAg		 HLA-restriction		 HLA		 Overall		 mHAg		 mHAg	tissue	distribution	 Reference
	 disparityA	 molecule	 frequencyB	 applicability	 gene
HA-1 24% HLA-A2 43% 10.6% HA-1 Hematopoietic cells, myeloid and lymphoid  (29)
      leukemic cells
HA-2 4% HLA-A2 43% 1.7% Myosin 1G Hematopoietic cells, myeloid and lymphoid  (15)
      leukemic cells
HB-1H/Y C 6%/24% HLA-B44 12% 0.7%/2.9% Unknown B cell ALL (16)
ACC-1 17% HLA-A24 34% 5.8% BCL2A1 Hematopoietic cells, myeloid and lymphoid  (27)
      leukemic cells
ACC-2 17% HLA-B44 12% 2.7% BCL2A1 Hematopoietic cells, myeloid and lymphoid  (27)
      leukemic cells
UGT2B17 11% HLA-A29 5% 0.6% UGT2B17 DCs, B cells (17)
LRH-1 13%D HLA-B7 11% 1.4% P2X5 T cells, B cells, NK cells, myeloid leukemic (28)
       progenitor cells
B8/H-Y 25% HLA-B8 8% 2.0% UTY Hematopoietic cells (30)
ADisparity within the transplant pairs with the correct HLA allele. Calculations were based on the reported allele frequencies under the assumption of an 
HLA-matched unrelated donor. BPhenotype frequencies were calculated based on global allele frequencies reported in dbMHC (http://www.ncbi.nlm.
nih.gov/mhc). CHB-1 can be recognized bidirectionally. Data represent, respectively, the disparity for HB-1H and HB-1Y as positive alleles. DIt has not 
been reported whether the disparity rate for LRH-1 was determined in HLA-matched sibling pairs or in HLA-matched unrelated donor/recipient pairs. 
ALL, acute lymphocytic leukemia.
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peptide  is  by  definition  present  on  the 
cell surface (14, 15). The recent determi-














































































Implications of LRH-1 use  
for adoptive immunotherapy
The  novel  mHAg  LRH-1  is  encoded  by 
the hematopoietic system–specific P2X5 
gene,  which  has  interesting  properties 
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Flushing out the role of GPR109A (HM74A)  
in the clinical efficacy of nicotinic acid
Nicholas B. Pike







































Identification and function of Gi 
protein–coupled receptors for 
nicotinic acid
In 2003, several groups published stud-
ies  showing  that  the  orphan  receptor 
GPR109A is activated by nicotinic acid at 
concentrations consistent with the expo-
sure achieved following therapeutic doses 
(5–7). Furthermore, additional compounds 
with a clinical profile similar to that of nic-
otinic acid (e.g., acipimox and acifran) were 
also confirmed as full agonists of GPR109A. 
Importantly, nicotinamide, which does not 
alter  lipoprotein profiles but shares the 
vitamin-like properties of nicotinic acid, 
has virtually no GPR109A agonist activity. 
This pharmacological profile strongly sug-
gests that GPR109A is a molecular target 
involved in the clinical efficacy of nicotinic 
acid and therefore offers a potential focus 
to explore the biological processes involved 
in the highly desirable therapeutic profile 
achieved following chronic treatment with 
this drug (8–9).
The best-described action of nicotinic 
acid is the inhibition of adipocyte lipolysis. 
